Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation

References

• Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303–308
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–848
   PubMed Web of Science ®Google Scholar
• Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41–44
   PubMed Web of Science ®Google Scholar
• Siddique SS, Shah R, Suelves AM, et al. Road to remission: a comprehensive review of therapy in uveitis. Expert Opin Investig Drugs. 2011;20:1497–1515
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825–831
   PubMed Web of Science ®Google Scholar
• Durrani K, Zakka FR, Ahmed M, et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56:474–510
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81
   PubMedGoogle Scholar
• Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598
   PubMed Web of Science ®Google Scholar
• García-De-Vicuña C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22:90–95
   PubMed Web of Science ®Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28:15–23
   PubMed Web of Science ®Google Scholar
• Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73:75–97
   PubMed Web of Science ®Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73:39–47
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55
   PubMed Web of Science ®Google Scholar
• Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut. 2013;62:201–208
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234–235
   PubMed Web of Science ®Google Scholar
• Sen HN, Sangave AA, Goldstein DA, et al. A standardized grading system for scleritis. Ophthalmology. 2011;118:768–771
   PubMed Web of Science ®Google Scholar
• Avery RL, Fekrat S, Hawkins BS, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16:183–189
   PubMed Web of Science ®Google Scholar
• Holbrook JT, Kempen JH, Prusakowski NA, et al. Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial—lessons for comparative effectiveness trials. Clin Trials. 2011;8:736–743
   PubMed Web of Science ®Google Scholar
• Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res. 2010;29:610–621
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behcet’s uveitis: an open-label trial. Rheumatol Int. 2008;29:53–57
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50:593–597
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34:1146–1150
   PubMed Web of Science ®Google Scholar
• Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358–364
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford). 2012;51:2204–2214
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011;33:541–550
   PubMed Web of Science ®Google Scholar
• Furuta S, Chow YW, Chaudhry AN, et al. Switching of anti-TNF-α agents in Behçet’s disease. Clin Exp Rheumatol. 2012;30:S62–S68
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54–S57
   PubMed Web of Science ®Google Scholar
• Simonini G, Katie D, Cimaz R, et al. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014;44:39--46
   Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16--23
   PubMed Web of Science ®Google Scholar
• Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2012;31:90–91
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323–1332
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292
   PubMed Web of Science ®Google Scholar